24 Result(s)

Article

Hypersensitivity reactions related to oxaliplatin (OHP)

Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions related to oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected ...

G Brandi, M A Pantaleo, C Galli, A Falcone, A Antonuzzo… in British Journal of Cancer (2003)

Article

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

Docetaxel (75 mg m⁻² 3-weekly) is standard second-line treatment in advanced non-small-cell lung cancer (NSCLC) with significant toxicity. To verify whether a weekly schedule (33.3 mg m⁻² for 6 weeks) improved qu...

C Gridelli, C Gallo, M Di Maio, E Barletta, A Illiano… in British Journal of Cancer (2004)

Article

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer

The aim of the study was to determine whether modulation of 5-fluorouracil (FU) by methotrexate (MTX) improves survival compared to FU+6-s-leucovorin (LV) following potentially curative resection of stage II and ...

A Sobrero, G Frassineti, A Falcone, L Dogliotti, R Rosso… in British Journal of Cancer (2005)

Article

Erratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer

A Sobrero1, G Frassineti2, A Falcone3, L Dogliotti4, R Rosso5, F Di Costanzo6 and P Bruzzi5 on behalf of the INTACC7 Correction to: British Journal of Cancer (2004) 92, 24–29. doi:10.1038/sj.bjc.6602276 Owing ...

A Sobrero, G Frassineti, A Falcone, L Dogliotti, R Rosso… in British Journal of Cancer (2005)

Article

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small...

C Tibaldi, T Prochilo, F Russo, M C Pennucci, A Del Freo… in British Journal of Cancer (2006)

Article

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer

Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxe...

L Galli, A Fontana, C Galli, L Landi, E Fontana, A Antonuzzo… in British Journal of Cancer (2007)

Article

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

This multicenter phase II study evaluated, in chemonaive patients with stage IIIB–IV NSCLC, age ⩾70 and with a performance status 0–2, the activity, efficacy and tolerability of planned sequential administrati...

C Tibaldi, E Vasile, A Antonuzzo, R Di Marsico, A Fabbri… in British Journal of Cancer (2008)

Article

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

The pharmacokinetics (PK) and pharmacodynamics (PD) of metronomic irinotecan have not been studied in cancer patients. The aim of the study is to investigate the PK/PD profile of irinotecan/SN-38 administered ...

G Allegrini, A Falcone, A Fioravanti, M T Barletta, P Orlandi… in British Journal of Cancer (2008)

Article

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

Metronomic chemotherapy refers to the administration of chemotherapy at low, nontoxic doses on a frequent schedule with no prolonged breaks. The aim of the study is to rationally develop a CPT-11 metronomic re...

G Bocci, A Falcone, A Fioravanti, P Orlandi, A Di Paolo… in British Journal of Cancer (2008)

Article

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy

We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC). The t...

F Graziano, A Ruzzo, F Loupakis, D Santini, V Catalano… in British Journal of Cancer (2008)

Article

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

The objective of this study was to investigate the efficacy of first-line chemotherapy containing irinotecan and/or oxaliplatin in patients with advanced mucinous colorectal cancer. Prognostic factors associat...

V Catalano, F Loupakis, F Graziano, U Torresi, R Bisonni… in British Journal of Cancer (2009)

Article

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substitut...

E Vasile, G Masi, L Fornaro, S Cupini, F Loupakis, S Bursi… in British Journal of Cancer (2009)

Article

Do we need biopsies of metastases for colorectal cancer patients?

I Floriani, D Santini, V Torri, C Cremolini, A Falcone… in British Journal of Cancer (2009)

Article

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional KRAS mutati...

F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore… in British Journal of Cancer (2009)

Article

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)

The conventional treatment options for advanced gastric patients remain unsatisfactory in terms of response rate, response duration, toxicity, and overall survival benefit. The purpose of this phase II study w...

C Pinto, F Di Fabio, C Barone, S Siena, A Falcone, S Cascinu… in British Journal of Cancer (2009)

Article

Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

C Cremolini, A Ruzzo, F Graziano, A Falcone, F Loupakis in British Journal of Cancer (2010)

Article

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC).

F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore… in British Journal of Cancer (2011)

Article

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients

Epidermal growth factor receptor (EGFR) promoter methylation may be responsible for the loss of EGFR expression in neoplastic cells. The primary aim of our study was to verify a possible correlation between EGFR ...

M Scartozzi, I Bearzi, A Mandolesi, R Giampieri, L Faloppi… in British Journal of Cancer (2011)

Article

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

The FOLFOXIRI regimen produces a high rate of radiological and histopathological responses. Bevacizumab added to chemotherapy showed an improvement in pathological response and necrosis of colorectal liver met...

F Loupakis, M Schirripa, C Caparello, N Funel, L Pollina… in British Journal of Cancer (2013)

Article

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

No data are available on the pharmacogenetics of metronomic chemotherapy in prostate cancer. The aim of this study was to evaluate the association between VEGF-A sequence variants and prostate-specific antigen (P...

P Orlandi, A Fontana, A Fioravanti, T Di Desidero, L Galli… in British Journal of Cancer (2013)